What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer? [0.03%]
HER2阳性乳腺癌的新辅助治疗如何做到精准且优化？
Daniel S Peiffer,Caitlin Maloney,Nan Chen
Daniel S Peiffer
HER2-positive breast cancer accounts for approximately 15%-20% of breast cancers and was historically associated with poor outcomes. The introduction of HER2-targeted therapies has significantly improved prognosis, particularly in the treat...
Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity [0.03%]
多靶点粪便DNA检测与粪便免疫化学法检测的后续结肠镜检查：按种族和族裔进行的全国性评估
Mallik Greene,Brad Stieber,A Burak Ozbay et al.
Mallik Greene et al.
Background: Fecal immunochemical tests (FITs), fecal occult blood tests (FOBTs), and multitarget stool DNA (mt-sDNA) tests are convenient, noninvasive colorectal cancer (CRC) screening strategies. However, delays in or fa...
Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis [0.03%]
PD-L1在阴茎鳞癌中的预后价值：系统评价和Meta分析
Nadine Mahmoud,Arfa Mustasam,Justin Miller et al.
Nadine Mahmoud et al.
Background: Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy, with up to 40% of patients presenting with nodal metastasis and poor survival in advanced stages. PD-L1 is an immune checkpoint molecu...
Genetics-Supported Mainstream Testing Improves Access and Efficiency for Patients With Breast Cancer [0.03%]
遗传支持的主流检测提高乳腺癌患者的使用率和效率
Kristen M Shannon,Mackenzie Wooters,Geoffrey G Fell et al.
Kristen M Shannon et al.
Background: The demand for germline genetic testing in oncology is outpacing traditional genetics service capacity. Mainstream genetic testing, where oncologists initiate testing with structured support, may expand access...
Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers [0.03%]
学术型癌症中心开展健康公平性评价的试点研究及其启示——基于健康公平性报告卡（HERC）的方法学探索
Taneal D Carter,Ashley Orr,Carrie Richardson-Slater et al.
Taneal D Carter et al.
Background: The Health Equity Report Card (HERC) was developed to establish best practice recommendations and promote accountability among health systems in addressing care inequities. Recognizing the growing importance o...
A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial [0.03%]
骨髓移植虚拟现实心理社会干预试点随机临床试验(BMT-VR)
Hermioni L Amonoo,Richard Newcomb,Riley Psenka et al.
Hermioni L Amonoo et al.
Background: Patients undergoing bone marrow transplantation (BMT) experience significant physical and psychological symptoms. Scalable psychosocial interventions to reduce distress and improve quality of life (QoL) are li...
Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities [0.03%]
新冠肺炎疫情期间及疫情结束后的结直肠癌筛查的全国趋势：不同种族/族裔的差异与机会
Saeed Soleymanjahi,Nicolette Juliana Rodriguez,Young-Rock Hong et al.
Saeed Soleymanjahi et al.
Background: Although studies have reported on the impact of the COVID-19 pandemic on colorectal cancer (CRC) screening, data on long-term changes remain limited, particularly during the later phases of the pandemic (post ...
Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma [0.03%]
阿普利姆 ديسم治疗默克尔细胞癌疗效评估
Bryant Morocho,Sasha Lightfoot,Abdul Saied Calvino et al.
Bryant Morocho et al.
Background: The role of adjuvant immunotherapy (IO) in the treatment of Merkel cell carcinoma (MCC) is currently being explored in clinical trials. Here we aim to evaluate the real-world impact of adjuvant IO on survival ...
Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test [0.03%]
支付方对多癌症早期检测阳性受试者确认性诊断检查保险覆盖的看法
Julia R Trosman,Christine B Weldon,Allison W Kurian et al.
Julia R Trosman et al.
Background: Multicancer early detection (MCED) tests are not currently covered by most payers but have begun to emerge in clinical practice. Little is known about whether payers would cover confirmatory diagnostics that a...
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer [0.03%]
局灶性肌层浸润性膀胱癌患者中整体生存的中间临床终点的替代指标研究
Pietro Scilipoti,Mario de Angelis,Constance Thibault et al.
Pietro Scilipoti et al.
Background: Although intermediate clinical endpoints (ICEs) may expedite completion of randomized controlled trials (RCTs) evaluating perioperative systemic treatments for localized muscle-invasive bladder cancer (MIBC), ...